These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Preparation of a monoclonal antibody (HI30)-mitomycin C conjugate utilizing dextran T-40 and its specific cytotoxicity against human leukemia cell line CEM].
    Author: Zhu Z.
    Journal: Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1990 Aug; 12(4):274-80. PubMed ID: 1701360.
    Abstract:
    The anticancer drug mitomycin C (MMC) was conjugated with an affinity-purified murine monoclonal antibody (HI30) to a human T lymphocyte surface differentiation antigen with dextran T-40 as the intermediate carrier. The conjugate (HI30:MMC molar ratio, 1:7) retained full antibody binding activity as determined by an indirect immunofluorescence assay. E. Coli HB101 growth inhibition test showed that the antimicrobial activity [MMC equivalent (microgram/ml)] of the conjugate was about 29.2% as potent as free MMC. In a cytotoxicity test, the conjugate was about 3-10 times more cytotoxic against the antibody-reactive human T lymphocyte leukemia CEM cells than was free MMC or the mixture of HI30 and MMC [IC50 of the MMC equivalent (microgram/ml) was 0.4147, 2.212, 2.171, respectively] and was less cytotoxic against the antibody-nonreactive L1210 cells (IC50 were 1.311, 0.8683, 0.7308, respectively). The selective cytotoxicity was also confirmed by competitive inhibition with free antibody, showing a dependence on antibody binding of the target cell surface antigen. There was no detectable free MMC released from HI30-Dex-MMC conjugate stored at 4 degrees C for over one month as measured by chromatography on a Sephadex G-25 column.
    [Abstract] [Full Text] [Related] [New Search]